These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 3717302

  • 1. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
    Lee I, Radosevich JA, Chejfec G, Ma YX, Warren WH, Rosen ST, Gould VE.
    Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
    [Abstract] [Full Text] [Related]

  • 2. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG.
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical analysis of human pulmonary carcinomas using monoclonal antibody 44-3A6.
    Lee I, Radosevich JA, Ma YX, Combs SG, Rosen ST, Gould VE.
    Cancer Res; 1985 Nov; 45(11 Pt 2):5813-7. PubMed ID: 2414000
    [Abstract] [Full Text] [Related]

  • 4. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
    Chenard-Neu MP, Bellocq JP, Maier A, Batzenschlager A.
    Ann Pathol; 1990 Nov; 10(1):20-7. PubMed ID: 2328062
    [Abstract] [Full Text] [Related]

  • 5. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
    Zhu W, Michael CW.
    Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
    [Abstract] [Full Text] [Related]

  • 6. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE, Novelli L, Boddi V, Paglierani M, Dini S.
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [Abstract] [Full Text] [Related]

  • 7. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
    O'Hara CJ, Corson JM, Pinkus GS, Stahel RA.
    Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
    [Abstract] [Full Text] [Related]

  • 8. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT, Gentile P, Tarectecan A, Fuchs A.
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [Abstract] [Full Text] [Related]

  • 9. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma.
    Warhol MJ, Hickey WF, Corson JM.
    Am J Surg Pathol; 1982 Jun; 6(4):307-14. PubMed ID: 6287872
    [Abstract] [Full Text] [Related]

  • 10. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
    Dahlstrom JE, Maxwell LE, Brodie N, Zardawi IM, Jain S.
    Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
    [Abstract] [Full Text] [Related]

  • 11. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M, Hoogsteden HC, Van der Kwast TH.
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [Abstract] [Full Text] [Related]

  • 12. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen.
    Ernst CS, Atkinson B, Chianese D, Peters J, Perry M, Herlyn M, Koprowski H.
    Appl Pathol; 1986 Oct; 4(3):115-24. PubMed ID: 2885017
    [Abstract] [Full Text] [Related]

  • 13. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
    Müller AM, Franke FE, Müller KM.
    Pathobiology; 2006 Oct; 73(1):50-4. PubMed ID: 16785767
    [Abstract] [Full Text] [Related]

  • 14. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K, Battifora H, Burke JS.
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [Abstract] [Full Text] [Related]

  • 15. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG.
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [Abstract] [Full Text] [Related]

  • 16. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?
    Müller AM, Weichert A, Müller KM.
    Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199
    [Abstract] [Full Text] [Related]

  • 17. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H, Kibar Y, Güldür ME, Bakir K.
    Pathol Res Pract; 2009 Jul; 205(11):749-52. PubMed ID: 19573998
    [Abstract] [Full Text] [Related]

  • 18. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel.
    Sosolik RC, McGaughy VR, De Young BR.
    Mod Pathol; 1997 Jul; 10(7):716-9. PubMed ID: 9237183
    [Abstract] [Full Text] [Related]

  • 19. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.
    Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE.
    Am J Pathol; 1985 Nov; 121(2):235-47. PubMed ID: 2414994
    [Abstract] [Full Text] [Related]

  • 20. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG.
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.